Royalty Pharma plc - Ordinary Shares - Class A Forecast, price target & analysts
Royalty Pharma plc - Ordinary Shares - Class A Target price 2025 - Analyst rating & recommendation
Royalty Pharma plc - Ordinary Shares - Class A Classifications & Recommendation:
Royalty Pharma plc - Ordinary Shares - Class A Price Target
| Target Price | $39.60 |
| Price | $32.45 |
| Potential |
22.03%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Royalty Pharma plc - Ordinary Shares - Class A 2026 .
The average Royalty Pharma plc - Ordinary Shares - Class A target price is $39.60.
This is
22.03%
register free of charge
$42.00
29.43%
register free of charge
$33.00
1.69%
register free of charge
|
|
| A rating was issued by 8 analysts: 6 Analysts recommend Royalty Pharma plc - Ordinary Shares - Class A to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Royalty Pharma plc - Ordinary Shares - Class A stock has an average upside potential 2026 of
22.03%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.26 | 3.01 |
| 3.86% | 33.02% | |
| EBITDA Margin | 57.10% | 94.49% |
| 9.90% | 65.49% | |
| Net Margin | 37.63% | 29.18% |
| 21.47% | 22.46% |
5 Analysts have issued a sales forecast Royalty Pharma plc - Ordinary Shares - Class A 2025 . The average Royalty Pharma plc - Ordinary Shares - Class A sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Royalty Pharma plc - Ordinary Shares - Class A EBITDA forecast 2025. The average Royalty Pharma plc - Ordinary Shares - Class A EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast Royalty Pharma plc - Ordinary Shares - Class A 2025 . The average Royalty Pharma plc - Ordinary Shares - Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.91 | 1.97 |
| 24.51% | 3.14% | |
| P/E | 16.47 | |
| EV/Sales | 8.00 |
1 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast for earnings per share. The average Royalty Pharma plc - Ordinary Shares - Class A EPS is
This results in the following potential growth metrics and future valuations:
Royalty Pharma plc - Ordinary Shares - Class A...
Current Royalty Pharma plc - Ordinary Shares - Class A Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Locked
➜
Locked
|
Locked | Oct 25 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup:
Locked
➜
Locked
|
Oct 25 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
